MLKL inhibitor NSA attenuated the killing effect of IMB5036 on pancreatic cancer cells. IMB5036 stimulated translocation of MLKL and p-MLKL from cytoplasm to cell membrane.
Investigators ectopically expressed α1,4-N-acetylglucosaminyltransferase (α4GnT), the α1,4-linked N-acetylglucosamine biosynthetic enzyme, together with MUC6 in the human pancreatic cancer cell lines MIA PaCa-2 and PANC-1, neither of which expressed α4GnT and MUC6.
Researchers evaluated the anticancer effect of ACY-241, an HDAC6-selective inhibitor, on erlotinib-resistant pancreatic cancer cells that overexpressed HDAC6.
Researchers examined the proliferation and drug resistance effect of ADP-ribosylation factor like-4c (Arl4c) on pancreatic cancer cells. They explored the contribution of Arl4c high expression in pancreatic stellate cell activation.
RNA sequencing experiments were conducted on PANC-1 human pancreatic cancer cells treated with Docosahexaenoyl difluorodeoxycytidine (DHA–dFdC), dFdC, or vehicle control体外。
Therapeutic efficacy of antineoplastic agents possessing a selective target to the nucleus of the cancer cells could be enhanced through novel formulation approaches. Scientists showed that optimized formula enhanced cytotoxicity and apoptotic potential, compared with icariin (ICA)-raw, against pancreatic cancer cell lines.
MK8722 is a potent and systemic pan-AMPK activator. It is an effective, direct, allosteric activator of AMPK complex in many mammals. Scientists investigated the anti-pancreatic cancer cells effects of MK8722 on two different human pancreatic cancer cell lines.